BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Banskota S, Raguram A, Suh S, Du SW, Davis JR, Choi EH, Wang X, Nielsen SC, Newby GA, Randolph PB, Osborn MJ, Musunuru K, Palczewski K, Liu DR. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 2022;185:250-265.e16. [PMID: 35021064 DOI: 10.1016/j.cell.2021.12.021] [Cited by in Crossref: 55] [Cited by in F6Publishing: 35] [Article Influence: 55.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma NL, Zhang N, Yong WTL, Misbah S, Hashim F, Soon CF, Lim GP, Peng W, Sonne C. Use, exposure and omics characterisation of potential hazard in nanomaterials. Materials Today Advances 2023;17:100341. [DOI: 10.1016/j.mtadv.2023.100341] [Reference Citation Analysis]
2 Breier D, Peer D. Genome editing in cancer: Challenges and potential opportunities. Bioactive Materials 2023;21:394-402. [DOI: 10.1016/j.bioactmat.2022.08.013] [Reference Citation Analysis]
3 Marty I, Beaufils M, Fauré J, Rendu J. Gene therapies for RyR1-related myopathies. Current Opinion in Pharmacology 2023;68:102330. [DOI: 10.1016/j.coph.2022.102330] [Reference Citation Analysis]
4 Hansen S, Mcclements ME, Corydon TJ, Maclaren RE. Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases. Cells 2023;12:440. [DOI: 10.3390/cells12030440] [Reference Citation Analysis]
5 Alves CRR, Ha LL, Yaworski R, Lazzarotto CR, Christie KA, Reilly A, Beauvais A, Doll RM, de la Cruz D, Maguire CA, Swoboda KJ, Tsai SQ, Kothary R, Kleinstiver BP. Base editing as a genetic treatment for spinal muscular atrophy. bioRxiv 2023:2023. [PMID: 36711797 DOI: 10.1101/2023.01.20.524978] [Reference Citation Analysis]
6 Wang JY, Doudna JA. CRISPR technology: A decade of genome editing is only the beginning. Science 2023;379:eadd8643. [PMID: 36656942 DOI: 10.1126/science.add8643] [Reference Citation Analysis]
7 Lahr WS, Sipe CJ, Skeate JG, Webber BR, Moriarity BS. CRISPR-Cas9 base editors and their current role in human therapeutics. Cytotherapy 2023:S1465-3249(22)01051-9. [PMID: 36635153 DOI: 10.1016/j.jcyt.2022.11.013] [Reference Citation Analysis]
8 Buffa V, Alvarez Vargas JR, Galy A, Spinozzi S, Rocca CJ. Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders. Front Genome Ed 2022;4:997142. [PMID: 36698790 DOI: 10.3389/fgeed.2022.997142] [Reference Citation Analysis]
9 Shi J, Wang H, Wang Y, Peng Y, Huang X, Zhang Y, Geng H, Wang Y, Li X, Liu C, Liu C. Mitochondrion-targeting and in situ photocontrolled protein delivery via photocages. J Photochem Photobiol B 2023;238:112624. [PMID: 36521315 DOI: 10.1016/j.jphotobiol.2022.112624] [Reference Citation Analysis]
10 Oladejo M, Paulishak W, Wood L. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Semin Cancer Biol 2023;88:81-95. [PMID: 36526110 DOI: 10.1016/j.semcancer.2022.12.003] [Reference Citation Analysis]
11 Enrica Soprano, Ester Polo, Beatriz Pelaz, Pablo del Pino. Biomimetic cell-derived nanocarriers in cancer research. J Nanobiotechnology 2022;20:538. [PMID: 36544135 DOI: 10.1186/s12951-022-01748-4] [Reference Citation Analysis]
12 Palermo E, Alexandridi M, Di Carlo D, Muscolini M, Hiscott J. Virus-like particle - mediated delivery of the RIG-I agonist M8 induces a type I interferon response and protects cells against viral infection. Front Cell Infect Microbiol 2022;12:1079926. [PMID: 36590581 DOI: 10.3389/fcimb.2022.1079926] [Reference Citation Analysis]
13 Cheng J, Lin G, Wang T, Wang Y, Guo W, Liao J, Yang P, Chen J, Shao X, Lu X, Zhu L, Wang Y, Fan X. Massively Parallel CRISPR‐Based Genetic Perturbation Screening at Single‐Cell Resolution. Advanced Science 2022. [DOI: 10.1002/advs.202204484] [Reference Citation Analysis]
14 Jo DH, Jang HK, Cho CS, Han JH, Ryu G, Jung Y, Bae S, Kim JH. Visual function restoration in a mouse model of Leber congenital amaurosis via therapeutic base editing. Mol Ther Nucleic Acids 2023;31:16-27. [PMID: 36589710 DOI: 10.1016/j.omtn.2022.11.021] [Reference Citation Analysis]
15 Wang D, Fan X, Li M, Liu T, Lu P, Wang G, Li Y, Han J, Zhao J. Prime Editing in Mammals: The Next Generation of Precision Genome Editing. CRISPR J 2022;5:746-68. [PMID: 36512351 DOI: 10.1089/crispr.2022.0084] [Reference Citation Analysis]
16 VanDyke D, Taylor JD, Kaeo KJ, Hunt J, Spangler JB. Biologics-based degraders - an expanding toolkit for targeted-protein degradation. Curr Opin Biotechnol 2022;78:102807. [PMID: 36179405 DOI: 10.1016/j.copbio.2022.102807] [Reference Citation Analysis]
17 Kostyusheva AP, Brezgin SA, Ponomareva NI, Goptar IA, Nikiforova AV, Gegechkori VI, Poluektova VB, Turkadze KA, Sudina AE, Chulanov VP, Kostyushev DS. Antiviral Activity of CRISPR/Cas9 Ribonucleoprotein Complexes on a Hepatitis B Virus Model In Vivo. Mol Biol 2022;56:816-822. [DOI: 10.1134/s0026893322060097] [Reference Citation Analysis]
18 Li Q, Gao Y, Wang H. CRISPR-Based Tools for Fighting Rare Diseases. Life (Basel) 2022;12. [PMID: 36556333 DOI: 10.3390/life12121968] [Reference Citation Analysis]
19 Nishiyama T, Zhang Y, Cui M, Li H, Sanchez-Ortiz E, McAnally JR, Tan W, Kim J, Chen K, Xu L, Bassel-Duby R, Olson EN. Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy. Sci Transl Med 2022;14:eade1633. [PMID: 36417486 DOI: 10.1126/scitranslmed.ade1633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Willis JCW, Silva-Pinheiro P, Widdup L, Minczuk M, Liu DR. Compact zinc finger base editors that edit mitochondrial or nuclear DNA in vitro and in vivo. Nat Commun 2022;13:7204. [PMID: 36418298 DOI: 10.1038/s41467-022-34784-7] [Reference Citation Analysis]
21 Holcomb EA, Pearson AN, Jungles KM, Tate A, James J, Jiang L, Huber AK, Green MD. High-content CRISPR screening in tumor immunology. Front Immunol 2022;13:1041451. [PMID: 36479127 DOI: 10.3389/fimmu.2022.1041451] [Reference Citation Analysis]
22 Olshefsky A, Richardson C, Pun SH, King NP. Engineering Self-Assembling Protein Nanoparticles for Therapeutic Delivery. Bioconjug Chem 2022;33:2018-34. [PMID: 35487503 DOI: 10.1021/acs.bioconjchem.2c00030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Rohner E, Yang R, Foo KS, Goedel A, Chien KR. Unlocking the promise of mRNA therapeutics. Nat Biotechnol 2022;40:1586-600. [PMID: 36329321 DOI: 10.1038/s41587-022-01491-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Chavez M, Chen X, Finn PB, Qi LS. Advances in CRISPR therapeutics. Nat Rev Nephrol 2022. [PMID: 36280707 DOI: 10.1038/s41581-022-00636-2] [Reference Citation Analysis]
25 Kwon S, Giessen TW. Engineered Protein Nanocages for Concurrent RNA and Protein Packaging In Vivo. ACS Synth Biol 2022;11:3504-15. [PMID: 36170610 DOI: 10.1021/acssynbio.2c00391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Falabella M, Minczuk M, Hanna MG, Viscomi C, Pitceathly RDS. Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges. Nat Rev Neurol 2022. [PMID: 36257993 DOI: 10.1038/s41582-022-00715-9] [Reference Citation Analysis]
27 Li R, Wang Q, She K, Lu F, Yang Y. CRISPR/Cas systems usher in a new era of disease treatment and diagnosis. Mol Biomed 2022;3:31. [PMID: 36239875 DOI: 10.1186/s43556-022-00095-y] [Reference Citation Analysis]
28 Sui H, Xu X, Su Y, Gong Z, Yao M, Liu X, Zhang T, Jiang Z, Bai T, Wang J, Zhang J, Xu C, Luo M. Gene therapy for cystic fibrosis: Challenges and prospects. Front Pharmacol 2022;13:1015926. [DOI: 10.3389/fphar.2022.1015926] [Reference Citation Analysis]
29 Jo DH, Bae S, Kim HH, Kim J, Kim JH. In vivo application of base and prime editing to treat inherited retinal diseases. Progress in Retinal and Eye Research 2022. [DOI: 10.1016/j.preteyeres.2022.101132] [Reference Citation Analysis]
30 Demirci S, Essawi K, Germino-Watnick P, Liu X, Hakami W, Tisdale JF. Advances in CRISPR Delivery Methods: Perspectives and Challenges. CRISPR J 2022;5:660-76. [PMID: 36260301 DOI: 10.1089/crispr.2022.0051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Suh S, Choi EH, Raguram A, Liu DR, Palczewski K. Precision genome editing in the eye. Proc Natl Acad Sci U S A 2022;119:e2210104119. [PMID: 36122230 DOI: 10.1073/pnas.2210104119] [Reference Citation Analysis]
32 Ren D, Fisson S, Dalkara D, Ail D. Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy. Pharmaceutics 2022;14:1973. [PMID: 36145721 DOI: 10.3390/pharmaceutics14091973] [Reference Citation Analysis]
33 Salman A, Kantor A, Mcclements ME, Marfany G, Trigueros S, Maclaren RE. Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations. Pharmaceutics 2022;14:1842. [DOI: 10.3390/pharmaceutics14091842] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Lu C, Kuang J, Shao T, Xie S, Li M, Zhu L, Zhu L. Prime Editing: An All-Rounder for Genome Editing. Int J Mol Sci 2022;23. [PMID: 36077252 DOI: 10.3390/ijms23179862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 He J, Yu L, Lin X, Liu X, Zhang Y, Yang F, Deng W. Virus-Like Particles as Nanocarriers for Intracellular Delivery of Biomolecules and Compounds. Viruses 2022;14:1905. [DOI: 10.3390/v14091905] [Reference Citation Analysis]
36 Hamilton JR, Chen E, Perez BS, Sandoval Espinoza CR, Doudna JA. Cell type-programmable genome editing with enveloped delivery vehicles.. [DOI: 10.1101/2022.08.24.505004] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Luo N, Zhong W, Li J, Lu J, Dong R. CRISPR/dCas9 for hepatic fibrosis therapy: implications and challenges. Mol Biol Rep 2022. [PMID: 35960410 DOI: 10.1007/s11033-022-07713-6] [Reference Citation Analysis]
38 Zhuo C, Tao Y, Li M. Engineered virus-like particles: paving the way for effective somatic genome editing. Signal Transduct Target Ther 2022;7:279. [PMID: 35961953 DOI: 10.1038/s41392-022-01089-6] [Reference Citation Analysis]
39 Lyu P, Lu B. New Advances in Using Virus-like Particles and Related Technologies for Eukaryotic Genome Editing Delivery. Int J Mol Sci 2022;23:8750. [PMID: 35955895 DOI: 10.3390/ijms23158750] [Reference Citation Analysis]
40 Tirolle V, Krug A, Bokobza E, Bulcaen M, Ensinck MM, Geurts MH, Hendriks D, Vermeulen F, Larbret F, Gutierrez-guerrero A, Medaer L, Gijsbers R, Mangeot PE, Clevers H, Carlon MS, Bost F, Verhoeyen E. Nanoblades allow high-level genome editing in organoids.. [DOI: 10.1101/2022.08.04.502859] [Reference Citation Analysis]
41 Katti A, Foronda M, Zimmerman J, Zafra MP, Goswami S, Gardner EE, Diaz BJ, Simon JM, Wuest A, Luan W, Fernandez MTC, Kadina AP, Walker JA, Holden K, Sánchez Rivera FJ, Lowe SW, Dow LE. Rapid generation of precision preclinical cancer models using regulatable in vivo base editing.. [DOI: 10.1101/2022.08.03.502708] [Reference Citation Analysis]
42 Dobrowolski C, Paunovska K, Schrader Echeverri E, Loughrey D, Da Silva Sanchez AJ, Ni H, Hatit MZC, Lokugamage MP, Kuzminich Y, Peck HE, Santangelo PJ, Dahlman JE. Nanoparticle single-cell multiomic readouts reveal that cell heterogeneity influences lipid nanoparticle-mediated messenger RNA delivery. Nat Nanotechnol 2022;17:871-9. [PMID: 35768613 DOI: 10.1038/s41565-022-01146-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Davis JR, Wang X, Witte IP, Huang TP, Levy JM, Raguram A, Banskota S, Seidah NG, Musunuru K, Liu DR. Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors. Nat Biomed Eng 2022. [PMID: 35902773 DOI: 10.1038/s41551-022-00911-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
44 Kaukonen M, McClements ME, MacLaren RE. CRISPR DNA Base Editing Strategies for Treating Retinitis Pigmentosa Caused by Mutations in Rhodopsin. Genes (Basel) 2022;13:1327. [PMID: 35893064 DOI: 10.3390/genes13081327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Raguram A, Banskota S, Liu DR. Therapeutic in vivo delivery of gene editing agents. Cell 2022;185:2806-27. [PMID: 35798006 DOI: 10.1016/j.cell.2022.03.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
46 Karasev MM, Baloban M, Verkhusha VV, Shcherbakova DM. Nuclear Localization Signals for Optimization of Genetically Encoded Tools in Neurons. Front Cell Dev Biol 2022;10:931237. [PMID: 35927988 DOI: 10.3389/fcell.2022.931237] [Reference Citation Analysis]
47 Huang X, Yang D, Zhang J, Xu J, Chen YE. Recent Advances in Improving Gene-Editing Specificity through CRISPR–Cas9 Nuclease Engineering. Cells 2022;11:2186. [DOI: 10.3390/cells11142186] [Reference Citation Analysis]
48 Lu ZH, Li J, Dmitriev IP, Kashentseva EA, Curiel DT. Efficient Genome Editing Achieved via Plug-and-Play Adenovirus Piggyback Transport of Cas9/gRNA Complex on Viral Capsid Surface. ACS Nano 2022. [PMID: 35749339 DOI: 10.1021/acsnano.2c00909] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Su J, She K, Song L, Jin X, Li R, Zhao Q, Xiao J, Chen D, Cheng H, Lu F, Wei Y, Yang Y. In vivo base editing rescues photoreceptors in a mouse model of retinitis pigmentosa.. [DOI: 10.1101/2022.06.20.496770] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Paul A, Collins MG, Lee HY. Gene Therapy: The Next-Generation Therapeutics and Their Delivery Approaches for Neurological Disorders. Front Genome Ed 2022;4:899209. [PMID: 35832929 DOI: 10.3389/fgeed.2022.899209] [Reference Citation Analysis]
51 de Grip WJ, Ganapathy S. Rhodopsins: An Excitingly Versatile Protein Species for Research, Development and Creative Engineering. Front Chem 2022;10:879609. [DOI: 10.3389/fchem.2022.879609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
52 Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer. Front Oncol 2022;12:919072. [DOI: 10.3389/fonc.2022.919072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
53 Fox TA, Houghton BC, Booth C. Gene Edited T Cell Therapies for Inborn Errors of Immunity. Front Genome Ed 2022;4. [DOI: 10.3389/fgeed.2022.899294] [Reference Citation Analysis]
54 Kwon S, Giessen TW. Engineered protein nanocages for concurrent RNA and protein packaging in vivo.. [DOI: 10.1101/2022.06.16.496435] [Reference Citation Analysis]
55 Liu N, Olson EN. CRISPR Modeling and Correction of Cardiovascular Disease. Circ Res 2022;130:1827-50. [PMID: 35679361 DOI: 10.1161/CIRCRESAHA.122.320496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
56 Pak AJ, Gupta M, Yeager M, Voth GA. Inositol Hexakisphosphate (IP6) Accelerates Immature HIV-1 Gag Protein Assembly toward Kinetically Trapped Morphologies. J Am Chem Soc 2022. [PMID: 35666943 DOI: 10.1021/jacs.2c02568] [Reference Citation Analysis]
57 Alsing S, Lindholm AB, Haldrup J, Jensen EG, Mikkelsen JG, Aagaard L, Askou AL, Corydon T. Simple Autofluorescence-Restrictive Sorting of eGFP+ RPE Cells Allows Reliable Assessment of Targeted Retinal Gene Therapy. Front Drug Deliv 2022;2. [DOI: 10.3389/fddev.2022.898568] [Reference Citation Analysis]
58 Yuan Q, Gao X. Multiplex base- and prime-editing with drive-and-process CRISPR arrays. Nat Commun 2022;13:2771. [PMID: 35589728 DOI: 10.1038/s41467-022-30514-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Breyne K, Ughetto S, Rufino-Ramos D, Mahjoum S, Grandell EA, de Almeida LP, Breakefield XO. Exogenous loading of extracellular vesicles, virus-like particles, and lentiviral vectors with supercharged proteins. Commun Biol 2022;5:485. [PMID: 35590035 DOI: 10.1038/s42003-022-03440-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Caba C, Mohammadzadeh A, Tong Y. On the Study of Deubiquitinases: Using the Right Tools for the Job. Biomolecules 2022;12:703. [DOI: 10.3390/biom12050703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Stranford DM, Simons LM, Berman KE, Cheng L, Lucks JB, Hultquist JF, Leonard JN. Bioengineering multifunctional extracellular vesicles for targeted delivery of biologics to T cells.. [DOI: 10.1101/2022.05.14.491879] [Reference Citation Analysis]
62 Caruso SM, Quinn PM, da Costa BL, Tsang SH. CRISPR/Cas therapeutic strategies for autosomal dominant disorders. Journal of Clinical Investigation 2022;132:e158287. [DOI: 10.1172/jci158287] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
63 Lim TS. Delivering therapeutic proteins in vivo by engineered DNA-free virus-like particles. Commun Biol 2022;5:392. [PMID: 35477767 DOI: 10.1038/s42003-022-03338-4] [Reference Citation Analysis]
64 Leclerc D, Goujon L, Jaillard S, Nouyou B, Cluzeau L, Damaj L, Dubourg C, Etcheverry A, Levade T, Froissart R, Dréano S, Guillory X, Eriksson LA, Launay E, Mouriaux F, Belaud-rotureau M, Odent S, Gilot D. Gene editing is suitable to treat GM1 Gangliosidosis: a proof-of-concept study.. [DOI: 10.1101/2022.04.17.488473] [Reference Citation Analysis]
65 Edwardson TGW, Levasseur MD, Tetter S, Steinauer A, Hori M, Hilvert D. Protein Cages: From Fundamentals to Advanced Applications. Chem Rev 2022. [PMID: 35394752 DOI: 10.1021/acs.chemrev.1c00877] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
66 Lederer CW, Koniali L, Buerki-thurnherr T, Papasavva PL, La Grutta S, Licari A, Staud F, Bonifazi D, Kleanthous M. Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies. Pharmaceutics 2022;14:793. [DOI: 10.3390/pharmaceutics14040793] [Reference Citation Analysis]
67 Pak AJ, Gupta M, Yeager M, Voth GA. Inositol hexakisphosphate (IP6) accelerates immature HIV-1 Gag protein assembly towards kinetically-trapped morphologies.. [DOI: 10.1101/2022.03.29.486265] [Reference Citation Analysis]
68 Harrison PT. CRISPR gene editing - what are the possibilities for respiratory medicine? Expert Rev Respir Med 2022;:1-4. [PMID: 35313109 DOI: 10.1080/17476348.2022.2056021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Liu C, Xu H, Yuan F, Chen W, Chen H, Sheng L, Wu Y, Li X. Identification of dominant conformational epitopes from the whole structure of the proprotein convertase subtilisin/kexin type 9. Biochem Biophys Res Commun 2022;606:55-60. [PMID: 35339752 DOI: 10.1016/j.bbrc.2022.03.066] [Reference Citation Analysis]
70 Grimm N, Lee JT. Selective Xi reactivation and alternative methods to restore MECP2 function in Rett syndrome. Trends in Genetics 2022. [DOI: 10.1016/j.tig.2022.01.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Bernard BE, Landmann E, Jeker LT, Schumann K. CRISPR/Cas-based Human T cell Engineering: Basic Research and Clinical Application. Immunology Letters 2022. [DOI: 10.1016/j.imlet.2022.03.005] [Reference Citation Analysis]
72 Becirovic E. Maybe you can turn me on: CRISPRa-based strategies for therapeutic applications. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-022-04175-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Wilson RC. Outsmarting Delivery Barriers In Vivo: Base Editing via Next-Generation Virus-Like Particles. GEN Biotechnology 2022;1:30-32. [DOI: 10.1089/genbio.2022.29012.rwi] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Crunkhorn S. Enhancing base editor delivery. Nat Rev Drug Discov. [DOI: 10.1038/d41573-022-00021-5] [Reference Citation Analysis]
75 . Synthetic viral lookalikes sneak gene-editing tools into cells. Nature 2022;601:300-300. [DOI: 10.1038/d41586-022-00068-9] [Reference Citation Analysis]
76 Yu J, Li T, Zhu J. Gene Therapy Strategies Targeting Aging-Related Diseases. Aging and disease 2022. [DOI: 10.14336/ad.2022.00725] [Reference Citation Analysis]
77 Radtke S, Kiem H. Bringing gene therapy to where it’s needed. Trends in Molecular Medicine 2022. [DOI: 10.1016/j.molmed.2022.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]